Kleinjan, J.P.; Blom, J.; van Beek, A.P.; Bouma, H.R.; van Dijk, P.R.
Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis. Metabolites 2024, 14, 162.
https://doi.org/10.3390/metabo14030162
AMA Style
Kleinjan JP, Blom J, van Beek AP, Bouma HR, van Dijk PR.
Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis. Metabolites. 2024; 14(3):162.
https://doi.org/10.3390/metabo14030162
Chicago/Turabian Style
Kleinjan, Jan P., Justin Blom, André P. van Beek, Hjalmar R. Bouma, and Peter R. van Dijk.
2024. "Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis" Metabolites 14, no. 3: 162.
https://doi.org/10.3390/metabo14030162
APA Style
Kleinjan, J. P., Blom, J., van Beek, A. P., Bouma, H. R., & van Dijk, P. R.
(2024). Balancing Risks and Benefits: Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Diabetic Ketoacidosis. Metabolites, 14(3), 162.
https://doi.org/10.3390/metabo14030162